[Which interventions are recommended in the last phase of Huntington disease?]

Michaela Hierhacker-Nosal1

  • 1, Reglergasse 3/208, 1220, Wien, Österreich. m.w.hierhacker@chello.at.

Insights

Advance care planning is crucial for Huntington Disease patients facing progressive physical, cognitive, and psychological decline. Engaging patients in end-of-life decisions ensures their wishes are respected when they can no longer communicate.

Area of Science:

  • Neurology
  • Palliative Care
  • Medical Ethics

Background:

  • Huntington Disease (HD) is a chronic, progressive neurodegenerative disorder.
  • HD significantly impacts patients' physical, cognitive, and psychological well-being over 10-30 years.
  • End-of-life challenges include communication loss, feeding difficulties, and respiratory insufficiency.

Purpose of the Study:

  • To emphasize the critical need for advance care planning in Huntington Disease.
  • To highlight the importance of patient involvement in end-of-life decision-making.
  • To address the challenges of life-sustaining measures in advanced HD.

Main Methods:

  • This study is a review of current understanding and clinical recommendations for Huntington Disease.
  • It synthesizes information on the progression of HD and its impact on patient autonomy.
  • Focuses on the ethical and practical considerations of end-of-life care.

Main Results:

  • Patients with advanced Huntington Disease often lose the ability to eat independently, requiring feeding tubes.
  • Respiratory insufficiency is common, sometimes necessitating tracheostomy.
  • Infections, particularly respiratory diseases, are frequent causes of death.

Conclusions:

  • Advance care planning is essential for Huntington Disease patients upon diagnosis.
  • Engaging patients in decisions about life-sustaining measures while they are capable ensures their autonomy.
  • Proactive planning facilitates dignified end-of-life care aligned with patient wishes.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
694
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
532
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
140
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
98
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
306